Diagonal Therapeutics raises $128M in Series A financing led by BVF Partners and Atlas Venture to develop agonist antibodies for hereditary hemorrhagic telangiectasia (HHT) and other severely debilitating diseases.
Diagonal Therapeutics raises $128M in Series A financing led by BVF Partners and Atlas Venture to develop agonist antibodies for hereditary hemorrhagic telangiectasia (HHT) and other severely debilitating diseases.
04/03/24, 10:12 AM
Location
cambridgeMoney raised
$128 million
Industry
therapeutics
biotechnology
health care
Round Type
series a
Investors
Checkpoint Capital, Velosity Capital, Viking Global Investors, Frazier Life Sciences, Ra Capital Management, Lightspeed Venture Partners, Atlas Venture, Bvf Partners
Diagonal Therapeutics, a biotechnology company, has launched with $128 million in Series A financing. The funding will support further advancement of the company’s proprietary DIAGONAL platform and pipeline of novel therapeutics to value-creating milestones.
Company Info
Location
cambridge, massachusetts, united states
Additional Info
Diagonal Therapeutics is a biotech company pioneering a new approach to discovering and developing agonist antibodies. The Company's DIAGONAL platform combines proprietary computational and experimental techniques to overcome historical challenges associated with agonist antibody drug discovery. Diagonal's emerging pipeline – discovered using the DIAGONAL platform – has the potential to deliver life-changing therapies to patients including therapies for hereditary hemorrhagic telangiectasia and pulmonary arterial hypertension. For more information, please visit www.diagonaltx.com.